EA201792399A1 - Пептидные композиции и способы использования - Google Patents

Пептидные композиции и способы использования

Info

Publication number
EA201792399A1
EA201792399A1 EA201792399A EA201792399A EA201792399A1 EA 201792399 A1 EA201792399 A1 EA 201792399A1 EA 201792399 A EA201792399 A EA 201792399A EA 201792399 A EA201792399 A EA 201792399A EA 201792399 A1 EA201792399 A1 EA 201792399A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
peptide compositions
photoreceptor
fas
ways
Prior art date
Application number
EA201792399A
Other languages
English (en)
Other versions
EA035293B1 (ru
Inventor
Кагри Г. Бесирли
Александер Дж. Бриджес
Джон К. Фрешли
Вильям А. Ханке
Линда Л. Джонсон
Френсис Х. Смит
Итан Сильвен
Дэвид Н. Закс
Original Assignee
ОЭнЭл ТЕРАПЬЮТИКС, ИНК.
Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОЭнЭл ТЕРАПЬЮТИКС, ИНК., Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган filed Critical ОЭнЭл ТЕРАПЬЮТИКС, ИНК.
Publication of EA201792399A1 publication Critical patent/EA201792399A1/ru
Publication of EA035293B1 publication Critical patent/EA035293B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В данном документе предоставлены композиции, включающие пептиды, их фармацевтические препараты и способы предотвращения с их помощью смерти фоторецепторов и защиты клеток сетчатки, включая, но без ограничения, фоторецепторные и пигментный эпителий сетчатки, от Fas- или TRAIL-опосредованного апоптоза.
EA201792399A 2015-05-01 2016-04-29 Пептидные композиции и способы использования EA035293B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Publications (2)

Publication Number Publication Date
EA201792399A1 true EA201792399A1 (ru) 2018-05-31
EA035293B1 EA035293B1 (ru) 2020-05-26

Family

ID=57217771

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201792399A EA035293B1 (ru) 2015-05-01 2016-04-29 Пептидные композиции и способы использования
EA202090184A EA202090184A3 (ru) 2015-05-01 2016-04-29 Пептидные композиции и способы использования

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202090184A EA202090184A3 (ru) 2015-05-01 2016-04-29 Пептидные композиции и способы использования

Country Status (22)

Country Link
US (4) US10508134B2 (ru)
EP (2) EP3997981A1 (ru)
JP (2) JP6884755B2 (ru)
KR (2) KR20240046280A (ru)
CN (2) CN113651873A (ru)
AU (1) AU2016258837B2 (ru)
BR (1) BR112017023479A2 (ru)
CA (1) CA2984154A1 (ru)
CY (1) CY1124911T1 (ru)
DK (1) DK3288379T3 (ru)
EA (2) EA035293B1 (ru)
ES (1) ES2906173T3 (ru)
HK (1) HK1251979A1 (ru)
HR (1) HRP20220138T1 (ru)
HU (1) HUE057883T2 (ru)
LT (1) LT3288379T (ru)
MX (1) MX2017014075A (ru)
PL (1) PL3288379T3 (ru)
PT (1) PT3288379T (ru)
RS (1) RS62866B1 (ru)
SI (1) SI3288379T1 (ru)
WO (1) WO2016178993A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10508134B2 (en) 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768301A4 (en) * 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
KR20220118499A (ko) * 2019-12-18 2022-08-25 셀라 테라퓨틱스, 엘엘씨 신경영양제, 세포자멸 신호전달 단편 억제제(FAS) 또는 FAS 리간드(FASL) 억제제, 종양 괴사 인자-α(TNF-α) 또는 TNF 수용체 억제제, 미토콘드리아 펩티드, 올리고뉴클레오티드, 케모카인 억제제 또는 시스테인-아스파틱 프로테아제 억제제를 포함하는 약물 전달 시스템
WO2023129766A1 (en) * 2021-12-27 2023-07-06 Onl Therapeutics, Inc. Sfasl for inhibiting rpe cell death and associated disorders
WO2024031022A2 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use
WO2024031024A1 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 Ｃ末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
CA2561809A1 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
EP1737483A2 (en) 2004-04-23 2007-01-03 University of Pittsburgh of the Commonwealth System of Higher Education Cell death modulation via antagonists of fasl and fas activation
DK1885336T3 (da) * 2005-05-10 2009-05-25 Alcon Inc Suspensionsformuleringer, der omfatter et aktivt princip, et overfladeaktivt poloxamer- eller meroxapolmiddel og en glycol, samt deres anvendelse til fremstilling af et medikament til behandling af öjenlidelser
CA2628570A1 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
JP2009518308A (ja) * 2005-12-01 2009-05-07 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション アポトーシスを阻害するための化合物及び方法
CA2708549C (en) * 2007-12-21 2014-04-01 Stryker Corporation Bmp mutants with decreased susceptibility to noggin
WO2010102052A2 (en) * 2009-03-03 2010-09-10 The Regents Of The University Of Michigan Methods of inhibiting photoreceptor apoptosis
KR20120022721A (ko) * 2009-03-30 2012-03-12 산텐 세이야꾸 가부시키가이샤 ＪＮＫ(ｃ-Ｊｕｎ 아미노 말단 키나제) 저해 펩티드를 이용한 망막 질환의 예방 또는 치료제, 망막 질환의 예방 또는 치료 방법, 및 이 펩티드의 용도
EP2462128B1 (en) * 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
RU2637085C2 (ru) * 2011-06-06 2017-11-29 КИНЕТА УАН, ЭлЭлСи Фармацевтические композиции на основе shk и способы их получения и использования
CA2861543C (en) 2012-01-18 2022-05-31 Governing Council Of The University Of Toronto Novel peptides and methods and uses thereof for preventing retinal disorders
JP6087429B2 (ja) * 2012-06-21 2017-03-01 ハノル バイオファーマ カンパニー リミテッドＨａｎａｌｌ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途
AU2013337702A1 (en) * 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
JP2018510359A (ja) 2015-02-05 2018-04-12 イミューンアレイ ユーエスエイ インコーポレイテッド 脳損傷または神経変性を診断するための方法および組成物
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
EA035293B1 (ru) * 2015-05-01 2020-05-26 ОЭнЭл ТЕРАПЬЮТИКС, ИНК. Пептидные композиции и способы использования
KR20190096329A (ko) 2016-07-05 2019-08-19 유니버시티 오브 매사추세츠 녹내장에서 신경보호 요법으로서 sfasl의 aav2-매개된 유전자 전달
EP3768301A4 (en) 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
EP3810082A1 (en) 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10508134B2 (en) 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use
US10829518B2 (en) 2015-05-01 2020-11-10 Onl Therapeutics. Inc. Peptide compositions and methods of use

Also Published As

Publication number Publication date
KR20170140383A (ko) 2017-12-20
MX2017014075A (es) 2018-07-06
HK1251979A1 (zh) 2019-05-10
US20200123201A1 (en) 2020-04-23
US20210094985A1 (en) 2021-04-01
CA2984154A1 (en) 2016-11-10
PL3288379T3 (pl) 2022-03-07
EP3288379A4 (en) 2018-10-24
CN113651873A (zh) 2021-11-16
EP3288379A1 (en) 2018-03-07
BR112017023479A2 (pt) 2018-07-24
ES2906173T3 (es) 2022-04-13
US20180291062A1 (en) 2018-10-11
EA202090184A2 (ru) 2020-05-31
US20230287052A1 (en) 2023-09-14
PT3288379T (pt) 2022-02-08
WO2016178993A1 (en) 2016-11-10
EA035293B1 (ru) 2020-05-26
CN107708416B (zh) 2021-06-29
KR20240046280A (ko) 2024-04-08
KR102652804B1 (ko) 2024-04-01
CY1124911T1 (el) 2023-01-05
HRP20220138T1 (hr) 2022-05-27
JP2021120400A (ja) 2021-08-19
LT3288379T (lt) 2022-02-25
JP6884755B2 (ja) 2021-06-09
US11597749B2 (en) 2023-03-07
AU2016258837A1 (en) 2017-11-09
RS62866B1 (sr) 2022-02-28
US10508134B2 (en) 2019-12-17
HUE057883T2 (hu) 2022-06-28
AU2016258837B2 (en) 2020-12-03
DK3288379T3 (da) 2022-02-07
SI3288379T1 (sl) 2022-06-30
EP3288379B1 (en) 2021-11-03
EA202090184A3 (ru) 2020-07-31
US10829518B2 (en) 2020-11-10
JP2018514590A (ja) 2018-06-07
CN107708416A (zh) 2018-02-16
EP3997981A1 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
EA201792399A1 (ru) Пептидные композиции и способы использования
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201691582A1 (ru) Новые фармацевтические препараты
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201790533A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для модулирования экспрессии генов
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
EA201790922A1 (ru) Ингибиторы бромодомена
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
EA201991377A1 (ru) Композиции универсальной вакцины против гриппа
ZA201703467B (en) Methods of treating ocular conditions
EA202091567A1 (ru) Химерные белки мти
EA201600093A1 (ru) Дигидроксифенильные нейромедиаторные соединения, композиции и способы
EP3302531A4 (en) RECOMBINANT IMMUNE TOLERANCE ELASTINE-LIKE PEPTIDES WITHOUT IMMUNE TOLERANCE AND METHODS OF USE
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
WO2019036725A3 (en) PEPTIDE INHIBITORS OF TAU AGGREGATION
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении
EA201791456A1 (ru) Пептиды-антагонисты cgrp